CBLL
CeriBell, Inc. · Healthcare · Medical Devices
Last
$21.22
+$0.48 (+2.29%) 2:08 PM ET
Prev close $20.74
Open $20.18
Day high $21.55
Day low $20.18
Volume 159,157
Avg vol 281,761
Mkt cap
$772.77M
P/E ratio
-14.43
FY Revenue
$89.06M
EPS
-1.47
Gross Margin
87.89%
Sector
Healthcare
AI report sections
CBLL
CeriBell, Inc.
CeriBell exhibits strong medium- to long-horizon price appreciation alongside ongoing operating losses and negative free cash flow. Valuation multiples such as P/S and EV/Sales appear elevated relative to current profitability and cash generation, while the balance sheet shows low leverage and substantial liquidity. Technical indicators point to bullish momentum with recent breakout characteristics, set against heightened volatility and a moderate level of short interest.
AI summarized at 12:39 PM ET, 2026-04-15
AI summary scores
INTRADAY: 63 SWING: 67 LONG: 44
Volume vs average
Intraday (cumulative)
+33% (Above avg)
Vol/Avg: 1.33×
RSI
66.27 (Strong)
Strong (60–70)
MACD momentum
Intraday
-0.00 (Weak)
MACD: -0.01 Signal: -0.01
Short-Term
+0.31 (Strong)
MACD: 0.23 Signal: -0.08
Long-Term
+0.27 (Strong)
MACD: -0.30 Signal: -0.57
Intraday trend score 75.79

Latest news

CBLL 2 articles Positive: 2 Neutral: 0 Negative: 0
Positive GlobeNewswire Inc. • Jane Chao, Ph.D.
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates

Ceribell obtained FDA 510(k) clearance for its ClarityⓇ algorithm, becoming the first AI-powered point-of-care EEG technology capable of detecting electrographic seizures across all patient ages, from pre-term neonates to adults.

CBLL FDA clearance seizure detection neonatal care EEG monitoring AI algorithm
Sentiment note

Achieved significant FDA regulatory milestone, expanded technological capabilities, addressed critical unmet medical need in neonatal seizure detection

Positive GlobeNewswire Inc. • Ceribell, Inc.
Medtech Leader Erica Rogers Joins Ceribell Board of Directors

Medical technology company Ceribell announced the appointment of Erica Rogers to its Board of Directors, bringing over three decades of healthcare leadership experience to help expand nationwide access to their point-of-care EEG system.

CBLL BSX medical technology neurological conditions EEG board appointment
Sentiment note

Company is expanding leadership with an experienced executive, demonstrating strategic growth and potential for innovation

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal